ES2163511T3 - Preparacion farmaceutica conteniendo glucagon. - Google Patents

Preparacion farmaceutica conteniendo glucagon.

Info

Publication number
ES2163511T3
ES2163511T3 ES95919980T ES95919980T ES2163511T3 ES 2163511 T3 ES2163511 T3 ES 2163511T3 ES 95919980 T ES95919980 T ES 95919980T ES 95919980 T ES95919980 T ES 95919980T ES 2163511 T3 ES2163511 T3 ES 2163511T3
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
preparation containing
glucagon
containing glucagon
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95919980T
Other languages
English (en)
Inventor
Troels Kornfelt
Henrik Rasmussen
Flemming Steen Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2163511T3 publication Critical patent/ES2163511T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PREPARACION FARMACEUTICA QUE INCLUYE GLUCAGON Y UNA CANTIDAD ESTABILIZANTE DE UN AMFOLITO ACEPTABLE FARMACEUTICAMENTE, ESPECIALMENTE UN AMINOACIDO O DIPEPTIDO O UNA MEZCLA DE ESTOS Y OPCIONALMENTE UN EXCIPIENTE, MANTENIENDO SU ESTABILIDAD POR LARGOS PERIODOS DE TIEMPOS.
ES95919980T 1994-05-26 1995-05-26 Preparacion farmaceutica conteniendo glucagon. Expired - Lifetime ES2163511T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK59094 1994-05-26

Publications (1)

Publication Number Publication Date
ES2163511T3 true ES2163511T3 (es) 2002-02-01

Family

ID=8095292

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95919980T Expired - Lifetime ES2163511T3 (es) 1994-05-26 1995-05-26 Preparacion farmaceutica conteniendo glucagon.

Country Status (12)

Country Link
US (1) US5652216A (es)
EP (1) EP0760677B1 (es)
JP (1) JP3295430B2 (es)
AT (1) ATE205090T1 (es)
AU (1) AU694229B2 (es)
CA (1) CA2191317A1 (es)
DE (1) DE69522562T2 (es)
DK (1) DK0760677T3 (es)
ES (1) ES2163511T3 (es)
FI (1) FI964682A (es)
NO (1) NO965012L (es)
WO (1) WO1995032730A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US6384016B1 (en) * 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
AU2612599A (en) * 1998-03-13 1999-10-11 Novo Nordisk A/S Stabilized aqueous peptide solutions
JP2002193830A (ja) * 1998-10-19 2002-07-10 High Chem Co Ltd 経鼻投与用医薬製剤
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
EP1412384B1 (en) * 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
WO2004105790A1 (en) * 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN102940879B (zh) * 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US20050027005A1 (en) * 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
CN113304250A (zh) * 2003-11-20 2021-08-27 诺和诺德股份有限公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
JPWO2005110394A1 (ja) * 2004-05-19 2008-03-21 味の素株式会社 糖尿病治療薬
US8710181B2 (en) * 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
KR101340354B1 (ko) * 2004-11-12 2013-12-11 노보 노르디스크 에이/에스 안정한 펩티드 제제
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
EP4098177A1 (en) 2007-10-09 2022-12-07 DexCom, Inc. Integrated insulin delivery system with continuous glucose sensor
EP2203741B1 (en) 2007-10-25 2023-05-10 Dexcom, Inc. Systems and methods for processing sensor data
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
CN109157742B (zh) 2009-08-03 2022-04-05 因卡伯实验室有限责任公司 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法
EP2490708B1 (en) 2009-10-22 2013-03-27 Biodel Inc. Stabilized glucagon solutions
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
US8721620B2 (en) 2009-12-24 2014-05-13 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
WO2012012460A1 (en) * 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
BR112013023062B1 (pt) 2011-03-10 2022-01-18 Xeris Pharmaceuticals, Inc Solução estável para a injeção parenteral e método de fabricação da mesma
SG11201401921YA (en) 2011-10-31 2014-05-29 Xeris Pharmaceuticals Inc Formulations for the treatment of diabetes
WO2013086292A1 (en) * 2011-12-09 2013-06-13 Enject, Inc. Glucagon formulations
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
WO2015027173A1 (en) * 2013-08-22 2015-02-26 Zp Opco, Inc. Stable glucagon peptide formulations
US9782344B2 (en) * 2013-08-22 2017-10-10 Zp Opco, Inc. Stable glucagon peptide formulations
CN106573106B (zh) 2014-08-06 2021-06-22 Xeris药物公司 用于皮内和/或皮下注射糊剂的注射器、试剂盒和方法
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
AU2016287843B2 (en) * 2015-07-02 2021-06-17 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
KR20240036128A (ko) 2017-06-02 2024-03-19 엑스에리스 파머수티클스, 인크. 침전 방지 저분자 약물 제제
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27885A (da) * 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
DE3782737T3 (de) * 1987-08-21 1999-05-20 Imcera Group Inc., Northbrook, Ill. Stabilisierung von Wachstumshormonen.
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat

Also Published As

Publication number Publication date
FI964682A (fi) 1997-01-20
ATE205090T1 (de) 2001-09-15
NO965012D0 (no) 1996-11-25
US5652216A (en) 1997-07-29
DE69522562T2 (de) 2002-07-11
FI964682A0 (fi) 1996-11-25
JPH10500696A (ja) 1998-01-20
EP0760677B1 (en) 2001-09-05
WO1995032730A1 (en) 1995-12-07
JP3295430B2 (ja) 2002-06-24
CA2191317A1 (en) 1995-12-07
EP0760677A1 (en) 1997-03-12
DE69522562D1 (de) 2001-10-11
AU694229B2 (en) 1998-07-16
NO965012L (no) 1996-11-25
DK0760677T3 (da) 2001-12-31
AU2560695A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
ES2163511T3 (es) Preparacion farmaceutica conteniendo glucagon.
SE8804629D0 (sv) New therapeutically active compounds
HUP9701059A2 (hu) Stronciumsók alkalmazása ízületi bántalmak kezelésére alkalmas gyógyszerkészítmények előállítására
IL90550A0 (en) Amino acid derivatives,their manufacture and pharmaceutical compositions containing them
DE3686483D1 (de) Arzneimittel.
IL89427A0 (en) Amino acid derivatives,their manufacture and pharmaceutical compositions containing them
ES2062610T3 (es) Compuesto diarilico anti-ateroesclerotico.
DK394489D0 (da) Benzamid- og sulfonbenzamid-forbindelser, deres anvendelse til fremstilling af antiarytmiske laegemidler, farmaceutiske praeparater indeholdende forbindelserne og mellemprodukter ved fremstilling af forbindelserne
DE69512929D1 (de) Salze von aminoalkoholen und diese enthaltende pharmazeutische zusammensetzungen
PT87111A (pt) Process for the preparation of cyclic peptides and of pharmaceutical compositions containing the same
NO863373D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyre derivater.
DK370586D0 (da) N-(4-piperidyl)benzamid-forbindelser, 1-substituerede 4-aminopiperidiner til anvendelse som udgangsmateriale ved deres fremstilling og farmaceutiske praeparater
FI913034A0 (fi) Foerening med magsyrainhiberande effekt och foerfarande foer dess framstaellning.
PT87535A (pt) Process for the preparation of novel anf peptide derivatives and of pharmaceutical compositions containing the same
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
EE03803B1 (et) a-amino- ja tsüklopentaan-ß-aminohapet(-happeid) ja/või nende derivaate sisaldavad segud ja dipeptiidid, dipeptiidide valmistamismeetod ning nimetatud segusid ja/või dipeptiide sisaldavad ravimid
DK635988D0 (da) 1,3-butandiolacetoacetat-derivater og anvendelse af 1,3-butandiolacetoacetat-forbindelser til fremstilling af farmaceutiske praeparater
HUP9701293A2 (hu) Új, kellemetlen íztől mentes sók és ezeket tartalmazó gyógyszerkészítmények
MY104088A (en) Peptide-drugs compositions containing (alpha)-aminoboroic acid derivatives.
DK174885D0 (da) Derivater af n-(3-phenylmethylthio-1-oxopropyl)-aminoeddikesyre i form af enantiomere eller blandinger, fremgangsmaade til fremstilling af forbindelserne og laegemiddel indeholdende disse
KR970701559A (ko) 펩타이드의 경구 투여를 위한 안정화된 조성물(stabilized composition for oral administration of peptides)
NZ220852A (en) N-(imidazolylmethyl)-diphenylazomethine derivatives and pharmaceutical compositions
DK239289A (da) Antibioticum, betegnet gallidermin, og syreadditionssalte deraf, farmaceutiske og kosmetiske praeparater indeholdende forbindelserne og fremgangsmaade til forbindelsernes fremstilling
ITMI920368A0 (it) Composizioni farmaceutiche di derivati amminoacidi
IT8903497A0 (it) Somministrazione di miscele gassoseper uso terapeutico o medicinale ingenere

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 760677

Country of ref document: ES